Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Octagon Capital Advisors LP
Form 13F · Q2 2026

Octagon Capital Advisors LP

CIK 1839435Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$1.1B
Reported book value
27
Positions
12
Quarters on record
Top 50
Positions

Octagon Capital Advisors LP — holdings

Top 26 positions of 27, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1DNTH Dianthus Therapeutics Inc1.8M−5.4%$180M16.1%
2DFTX Definium Therapeutics Inc3.0M+20.9%$139M12.5%
3ABIVAX SA Abivax Sa993,000+46.7%$132M11.9%
4COGT Cogent Biosciences Inc2.4M+0.0%$91M8.2%
5ALMS Alumis Inc2.8M+0.0%$80M7.2%
6AVBP Arrivent Biopharma Inc2.0M+0.0%$68M6.2%
7TSHA Taysha Gene Therapies Inc9.7M+9.4%$66M5.9%
8BIOA Bioage Labs Inc1.7M+0.0%$43M3.9%
9MIRM Mirum Pharmaceuticals Inc338,900+0.0%$40M3.6%
10KYMR Kymera Therapeutics Inc310,000−27.1%$36M3.2%
11AKTS Aktis Oncology Inc960,847+0.0%$31M2.8%
12XENE Xenon Pharmaceuticals Inc490,000+0.0%$30M2.7%
13PALI Palisade Bio Inc10.3M+0.0%$21M1.9%
14OCUL Ocular Therapeutix Inc2.1M−34.5%$20M1.8%
15IRON Disc Medicine Inc270,000+0.0%$20M1.8%
16SMMT Summit Therapeutics Inc1.2M—$18M1.6%
17PHVS Pharvaris N V456,721+176.8%$16M1.4%
18ANL Adlai Nortye Ltd934,716—$11M1.0%
19DTIL Precision Biosciences Inc1.4M−39.6%$11M1.0%
20DBVT Dbv Technologies S A574,200+0.0%$9M0.8%
21FTH Faeth Therapeutics Inc361,010—$9M0.8%
22GYRE Gyre Therapeutics Inc954,416—$6M0.6%
23TRVI Trevi Therapeutics Inc315,000−78.8%$6M0.5%
24UNCY Unicycive Therapeutics Inc1.0M+0.0%$5M0.4%
25CNTX Context Therapeutics Inc3.0M−41.9%$2M0.2%
26GOSS Gossamer Bio Inc7.8M+0.0%$1M0.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.